Why Does Turalio Require a REMS Program for TGCT Treatment?
At a Glance
Turalio requires a REMS program because it can cause serious or life-threatening liver injury. The program requires prescriber certification, patient enrollment, certified pharmacy dispensing, and frequent liver blood tests to detect problems early.
In this answer
5 sections
Turalio (pexidartinib) is an oral medication used to treat eligible adults with symptomatic Tenosynovial Giant Cell Tumor (TGCT) that is not adequately manageable with surgery [1]. However, Turalio requires a special restricted safety program because it carries a risk of severe and potentially life-threatening liver injury [1][2]. This restricted safety program, called REMS (Risk Evaluation and Mitigation Strategy), is mandated by the FDA to ensure the medication’s benefits outweigh its risks. By requiring strict monitoring and regular blood tests, the program is designed to detect early signs of liver stress to reduce the risk of severe damage [1][3].
The Risk of Liver Injury (Hepatotoxicity)
Turalio carries an FDA “Boxed Warning” for hepatotoxicity, which is the medical term for drug-induced liver damage [1]. Clinical trials demonstrated that while many patients safely take the drug, a portion of patients developed serious, potentially fatal, or irreversible liver complications [4].
This liver injury can be mixed or cholestatic (affecting bile flow) [4]. In some rare cases, it has led to vanishing bile duct syndrome, a condition where the small tubes that carry bile inside the liver are permanently destroyed, which has resulted in the need for a liver transplant or fatal outcomes [5][4]. Because the potential consequences of this toxicity are so severe, the medication cannot be dispensed like a standard prescription [1].
What the REMS Program Means for You
To proactively manage and reduce the risk of severe liver damage, Turalio must be prescribed exclusively through the Turalio REMS Program [1][2]. This program puts strict safeguards in place for your care:
- Prescriber Certification: Your doctor must complete specialized education on liver toxicity and be officially certified by the REMS program to prescribe the drug [1].
- Patient Enrollment: You must be officially enrolled in the REMS program before you can receive your first dose [1].
- Controlled Dispensing: The medication is only available through certified pharmacies. These pharmacies must communicate with your doctor to ensure your safety checks and blood tests are up to date before dispensing your pills [1].
Why Regular Liver Tests Are Required
The core purpose of the REMS program is early detection, as your liver can sustain significant stress before you ever notice physical symptoms [3]. While monitoring reduces the risk, it cannot eliminate it entirely, and serious injury can still occur [1][4].
To monitor your liver’s health, you will undergo a baseline blood test before starting Turalio and continue with a very specific schedule of frequent blood draws throughout your treatment [1]. These blood tests monitor your liver enzymes (such as ALT, AST, and alkaline phosphatase) and bilirubin, a substance measured in blood that can rise when the liver or bile-flow system is affected [1].
The FDA prescribing information dictates an intensive testing timeline. While you must confirm the exact, current schedule with your care team, a typical timeline may involve weekly testing for the first 8 weeks, every two weeks for the following month, and every three months thereafter.
If your lab results reveal elevated liver enzymes or bilirubin, your doctor will follow specific, label-based guidelines to hold, reduce, or permanently discontinue your treatment [3]. Never adjust your dose on your own.
If You Notice Symptoms: Take Immediate Action
Do not wait for your next scheduled blood test if you feel unwell. Contact your prescriber IMMEDIATELY if you experience any of the following warning signs:
- Jaundice (yellowing of your skin or the whites of your eyes)
- Dark urine or pale, clay-colored stools
- Upper-right abdominal pain
- Severe itching
- Unusual bruising or bleeding
- Severe nausea or persistent vomiting
- Confusion or unusual fatigue
If you cannot reach your prescriber after hours, seek emergency medical care. Do not change, skip, or stop your dose on your own unless directly instructed by your clinician or an emergency care team.
Medication and Supplement Review
Before starting Turalio, you must give your prescriber and pharmacist a complete list of every prescription drug, over-the-counter medicine, vitamin, and herbal supplement you take. Some of these can interact with Turalio or affect your liver. Always check with your care team before starting any new medication or supplement while on Turalio.
Common questions in this guide
Why does Turalio have a REMS requirement for TGCT?
What do I need to do before I can receive Turalio?
How often will I need liver blood tests while taking Turalio?
What symptoms could mean Turalio is harming my liver?
Can my other medicines, supplements, or alcohol affect Turalio safety?
What happens if my liver tests become abnormal while I take Turalio?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Tenosynovial giant cell tumor.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my exact, scheduled timeline for blood tests during my first few months on Turalio?
- 2.Who should I contact if I experience symptoms of liver stress after regular clinic hours?
- 3.If my liver enzymes rise, what are the specific thresholds that would cause us to pause or permanently stop treatment?
- 4.Can we review my current list of medications, supplements, and alcohol use to ensure nothing will increase my liver risk?
References
References (5)
- 1
Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
Dharmani C, Wang E, Salas M, et al.
Future oncology (London, England) 2022; (18(13)):1595-1607 doi:10.2217/fon-2021-1475.
PMID: 35105158 - 2
TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment.
Waheed Rajper A, Dharmani C, Chilakapati L, et al.
Future oncology (London, England) 2025; (21(15)):1859-1865 doi:10.1080/14796694.2025.2509409.
PMID: 40438996 - 3
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment.
Dharmani C, Fofah O, Fallon M, et al.
Future oncology (London, England) 2024; (20(33)):2559-2564 doi:10.1080/14796694.2024.2373687.
PMID: 39023446 - 4
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, et al.
Lancet (London, England) 2019; (394(10197)):478-487 doi:10.1016/S0140-6736(19)30764-0.
PMID: 31229240 - 5
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
Piawah S, Hyland C, Umetsu SE, et al.
NPJ breast cancer 2019; (5()):17 doi:10.1038/s41523-019-0112-z.
PMID: 31240240
This page explains why Turalio requires REMS monitoring for educational purposes and does not replace medical advice. Follow your prescriber's instructions for blood tests, symptoms, and dose changes.